Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Erminia Massarelli, Robert I. Haddad, J. Jack Lee, Heather Y. Lin, Adam S. Garden, George R. Blumenschein, William Nassib William, Roy B. Tishler, Bonnie S. Glisson, Kathryn A. Gold, Faye M. Johnson, Guilherme Rabinowits, Lawrence E. Ginsberg, Michelle D. Williams, Jeffrey Myers, Merrill S. Kies, Vassiliki Papadimitrakopoulou
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2600419248